Impact of Multidrug-Resistant Bacteria in a Cohort of COVID-19 Critically Ill Patients: Data from a Prospective Observational Study Conducted in a High-Antimicrobial-Resistance-Prevalence Center
<b>Background</b>: Bacterial superinfections are common complications during viral infections, but the impact of multidrug-resistant (MDR) pathogens in critically ill patients affected by coronavirus disease 2019 (COVID-19) is still debated. <b>Methods</b>: This is an observational, monocentric, and prospective study designed to investigate the incidence, risk factors, and outcomes of MDR bacterial superinfections in COVID-19 patients admitted to the intensive care unit (ICU). <b>Results</b>: A high incidence of superinfections (66%, 159/241) was observed: ventilator-associated pneumonia (VAP) (65%, 104/159) and bloodstream infection (BSI, 32%, 51/159) were the most common. Superinfections, Extra-Corporeal Membrane Oxygenation (ECMO) support, and prone positioning increased the risk of death five, four, and more-than-two times, respectively (OR = 5.431, IC 95%: 1.637-18.014; 4.462, IC 95%: 1.616-12.324 and 2.346, IC 95%: 1.127-4.883). MDR bacteria were identified in 61% of patients with superinfection, with a cumulative incidence of 37.2% at day 14. Carbapenem-resistant <i>Acinetobacter baumannii</i> (CR-AB) and CR-<i>Klebsiella pneumoniae</i> (CR-KP) were the most common causative agents (24.3% and 13.7%). CR-AB was found to significantly increase both ICU and in-hospital mortality (76.4% and 78.2%), whereas CR-KP had no direct impact on mortality. Prior rectal colonization (<i>p</i> < 0.0001), mechanical ventilation (<i>p</i> = 0.0017), a prolonged ICU stay (<i>p</i> < 0.0001), the use of iNO (<i>p</i> = 0.0082), vasopressors (<i>p</i> = 0.0025), curarization (<i>p</i> = 0.0004), and prone positioning (<i>p</i> = 0.0084) were found to be risk factors for CR-AB. <b>Conclusions</b>: Critically ill COVID-19 patients are at high risk of developing MDR superinfection. While CR-KP had no direct impact on mortality, CR-AB appeared to increase ICU and in-hospital mortality.
Authors
- Luca Brazzi (ORCID: https://orcid.org/0000-0001-7059-0622)
- Claudia Filippini (ORCID: https://orcid.org/0000-0003-0194-142X)
- Vito Fanelli (ORCID: https://orcid.org/0000-0002-1647-2411)
- Gabriele Sales (ORCID: https://orcid.org/0000-0003-0891-2525)
- Marinella Zanierato
- Giorgia Montrucchio (ORCID: https://orcid.org/0000-0001-9341-965X)
- Silvia Corcione (ORCID: https://orcid.org/0000-0003-2949-4297)
- Antonio Curtoni (ORCID: https://orcid.org/0000-0001-8101-4196)
- Umberto Simonetti
- Francesco Giuseppe De Rosa (ORCID: https://orcid.org/0000-0001-8338-0130)
- Cristina Costa (ORCID: https://orcid.org/0000-0002-6549-4553)
- Eleonora Balzani (ORCID: https://orcid.org/0000-0001-7837-4457)
- Chiara Bonetto (ORCID: https://orcid.org/0000-0001-9895-6403)
- Giulia Gavanna
- Francesca Grillo
Institutions
- Tufts University (US)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- University of Turin (IT)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3390/jcm14020410
- Citations
- 4
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 5.58